Data / Drug companies / Emergent Product Development Gaithersburg Inc.
Emergent Product Development Gaithersburg Inc.: 5 products in the FDA NDC directory, labeler code 71665
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Emergent Product Development Gaithersburg Inc. (labeler code 71665) lists 5 products in the FDA National Drug Code Directory, covering 3 finished drugs by generic name. By type: 5 vaccines. Its main marketing category is biologics (BLA). The newest product started marketing on September 19, 2023.
The request: Watch Emergent Product Development Gaithersburg Inc. (FDA labeler code 71665): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 71665
- Products in commercial distribution
- 5
- Packages
- 5
- Finished drugs by generic name
- 3
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- August 31, 2007
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Biologics (BLA) | 5 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Vaccines | 5 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Smallpox and mpox (vaccinia) vaccine, live | 2 | 1 |
| Diluent for smallpox and mpox (vaccinia) vaccine, live | 2 | 1 |
| Anthrax vaccine adsorbed, adjuvanted | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 2 | 40% |
| Solution | 2 | 40% |
| Injection, suspension | 1 | 20% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Live Vaccinia Virus Vaccine | 2 |
| Live Attenuated Bacillus Anthracis Vaccine | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Cyfendus | 71665-001 | Injection, suspension | Biologics (BLA) | September 19, 2023 |
| Diluent for ACAM2000 | 71665-440 | Solution | Biologics (BLA) | August 31, 2007 |
| Acam2000 | 71665-430 | Injection, powder, lyophilized, for solution | Biologics (BLA) | August 31, 2007 |
| Diluent for ACAM2000 | 71665-340 | Solution | Biologics (BLA) | August 31, 2007 |
| Acam2000 | 71665-330 | Injection, powder, lyophilized, for solution | Biologics (BLA) | August 31, 2007 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.